Open AccessIn Vitro Activities of the Everninomicin SCH 27899 and Other Newer Antimicrobial Agents against Borrelia burgdorferi
Author(s) -
Lisa L. Dever,
Christine V. Torigian,
Alan G. Barbour
Publication year - 1999
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.43.7.1773
Subject(s) - microbiology and biotechnology , antimicrobial , cefepime , quinupristin , borrelia burgdorferi , dalfopristin , biology , meropenem , linezolid , antibacterial agent , antibiotics , antibiotic resistance , bacteria , imipenem , vancomycin , immunology , staphylococcus aureus , genetics , antibody
The in vitro activity of the everninomicin antibiotic SCH 27899 against 17 isolates ofBorrelia spp. was investigated. MICs ranged from 0.06 to 0.5 μg/ml. Time-kill studies with the B31 strain ofB. burgdorferi demonstrated ≥3-log10 -unit killing after 72 h with concentrations representing four times the MIC. The in vitro activity of four other newer antimicrobial agents, meropenem, cefepime, quinupristin-dalfopristin, and linezolid, was also tested against the B31 strain. Meropenem was the most potent of the latter agents, with an MIC of 0.125 μg/ml.